In terms of cell viability, it was shown that among a panel of cancer cell lines derived from hematologic malignancies and solid tumors, the MCL-1 inhibitor appeared to be the most potent in AML and multiple myeloma, showing IC50 values of <1 μM [23]. The gene discussed is MCL1; the disease is plasma cell myeloma.